<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02785250</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-DPX-Survivac-06</org_study_id>
    <nct_id>NCT02785250</nct_id>
  </id_info>
  <brief_title>Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoVaccine Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoVaccine Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunotherapeutic survivin vaccine DPX-Survivac, low dose oral cyclophosphamide, and IDO1
      inhibitor epacadostat will be tested together for the first time in patients with recurrent
      ovarian, fallopian tube, or peritoneal cancer to determine the safety and potential
      immune-modulating activity of the combination of these agents.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by adverse event reporting (CTCAE)</measure>
    <time_frame>up to 13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cell mediated immunity as measured by the antigen specific response in peripheral blood</measure>
    <time_frame>bimonthly for up to 13 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of treatment-induced changes in tumor infiltrating lymphocytes</measure>
    <time_frame>at 8 to 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>up to 13 months</time_frame>
    <description>Evaluated using modified RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>up to 13 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Recurrent Epithelial Ovarian Cancer</condition>
  <condition>Recurrent Fallopian Tube Cancer</condition>
  <condition>Recurrent Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Cyclophosphamide, Epacadostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DPX-Survivac</intervention_name>
    <description>SubQ injection</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epacadostat (INCB024360)</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal
             cancer

          -  Platinum-resistant or -sensitive after completing first-line treatment (debulking
             surgery and adjuvant or neoadjuvant treatment with standard of care treatment such as
             carboplatin and paclitaxel). Subjects may have had any number of subsequent lines of
             chemotherapy.

          -  Must have evidence of progressive disease with biochemical (i.e. rising CA-125) and/or
             radiologic progression

          -  Must have measurable disease by RECIST v1.1, a successful pre-treatment tumor biopsy,
             and be willing to undergo tumor biopsy during treatment

          -  Ambulatory with an ECOG 0-1

          -  Life expectancy â‰¥ 6 months

          -  Meet protocol-specified lab requirements

        Key Exclusion Criteria:

          -  Eligible for otherwise curative treatment or undergoing concurrent therapy

          -  Prior receipt of survivin based vaccines or immune checkpoint inhibitors (e.g.
             anti-CTLA-4, anti-PD-1, anti-PD-L1, or any other antibody or drug specifically
             targeting T cell co-stimulation) or an IDO inhibitor

          -  Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma
             in situ, or controlled bladder cancer

          -  Clinical ascites or metastatic pleural fluid

          -  Malignant bowel obstruction

          -  History of autoimmune disease requiring treatment within the last two years (except
             vitiligo or diabetes)

          -  Recent history of thyroiditis

          -  Presence of a serious acute infection or chronic infection

          -  Active central nervous system (CNS) or leptomeningeal metastasis (brain metastases)

          -  GI condition that might limit absorption of oral agents

          -  Other serious intercurrent chronic or acute illness, including myocardial infarction
             or cerebrovascular event within 6 months

          -  Ongoing treatment with steroid therapy or other immunosuppressive

          -  Receipt of monoamine oxidase inhibitors (MAOIs), UGT1A9 inhibitors, or melatonin
             supplements

          -  Acute or chronic skin and/or microvascular disorders

          -  Edema or lymphedema in the lower limbs &gt; grade 2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dona Bahmani</last_name>
      <phone>650-724-3308</phone>
      <email>dbahmani@stanford.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannine Villella, DO</last_name>
      <email>jvillella@northwell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sangmi Lee, RN, MSN</last_name>
      <phone>212-434-4482</phone>
      <email>slee52@northwell.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Sciences University, Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Clinical Trials Information Line</last_name>
      <phone>503-494-1080</phone>
      <email>trials@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Tanja Pejovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathi Lee Ybarra, BSN</last_name>
      <phone>215-614-0234</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Office</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>John Nemunaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Oza, MD</last_name>
      <phone>416-946-2818</phone>
      <email>amit.oza@uhn.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>IDO1 inhibitor</keyword>
  <keyword>ovarian</keyword>
  <keyword>fallopian tube</keyword>
  <keyword>peritoneal</keyword>
  <keyword>cancer</keyword>
  <keyword>recurrent</keyword>
  <keyword>tumor</keyword>
  <keyword>measurable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

